

BIOPAS, A SWIXX BIOPHARMA COMPANY, EXPANDS UCB PARTNERSHIP WITH ADDITIONAL BRANDS

Baar, Switzerland, March 17th, 2025 – Swixx BioPharma AG of Baar, Switzerland, and its affiliate Biopas, a Swixx BioPharma Company, announced the signature of an amended and restated Distributorship Agreement with UCB PHARMA, SA and/or UCB Pharma GmbH, expanding our existing partnership scope with UCB in CNS and immunology to include UCB Rare Disease portfolio. Under the Agreement, Biopas is appointed to distribute and commercialize fenfluramine, rozanolixizumab and zilucoplan sodium in Argentina and Colombia. Both companies are committed to ensuring that these important treatments reach patients in need, providing enhanced access to therapies for epilepsy and myasthenia gravis in both countries.

Marek Vasicek, MD, Chief Operations Officer Eurasia and R.O.W. expansion at Swixx BioPharma, commented: “We are pleased to expand our partnership with UCB. This agreement constitutes a clear recognition of the value Biopas brings to the table. Our extended collaboration is a testament to the strong trust and results Biopas and UCB have built together over the last years in Latam. At Swixx, we pride ourselves on providing tailor-made services that align with our partners' specific needs and expectations, ensuring the highest level of support and value. The same culture of excellence and commitment to delivering results is present at our new Latam subsidiary, Biopas, and we are grateful to UCB for their continued trust in our partnership.”

Pascal Forget, Regional General Manager Latam and Board Observer of Swixx, continued: “With this partnership extension, we are further solidifying our presence in the Rare Disease / CNS therapy area across Latin America. Biopas, a Swixx BioPharma Company, holds leading positions in these and several other key therapy areas, such as Immunology, Dermatology, Oncology and Gastroenterology and has an overall strong footprint in the region. With over 350 dedicated employees and presence in almost 20 countries in Latin America, we are strongly positioned to serve our partners and patients, ensuring access to innovative medicines to the ones that need them. We look forward to enhance collaboration with UCB as we work together to advance healthcare solutions in the region.”



About Swixx Group

Swixx operates 44 subsidiaries across Central and Eastern Europe, Greece, several CIS countries and the Middle East via Swixx BioPharma, via Biopas, a Swixx BioPharma company, in almost 20 countries in Latin America, and in Russia and Belarus via Swixx Healthcare. After the acquisition of Biopas, Swixx Group now has close to 1,700 employees and sales which exceeded 1.1 billion Euros in 2024. The company is one of the fastest-growing and largest independent commercialization platforms for biopharma globally. Swixx has gathered outstanding rare disease, oncology-hematology, specialty, vaccines and self-medication talent under one roof. For more information about Swixx, please visit: www.swixxbiopharma.com.



Swixx BioPharma inquiries:

Vedrana Sokac Brataljenovic, Public Affairs Director

vedrana.sokac@swixxbiopharma.com, Tel: +385 1 425 6086

Biopas inquiries:

Pascal Forget, Executive Regional General Manager Latam

bd@biopasgroup.com

